Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.

Anna KiialainenMarkus NiggliChristine L KemptonGiancarlo CastamanTiffany ChangIdo Paz-PrielJoanne I AdamkewiczGallia G Levy

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2022)

Clinically relevant improvements in HJHS were observed in younger PwHA and those with target joints after 48 weeks of emicizumab in HAVEN 3. Biomarkers of bone/joint health did not show significant changes during 72 weeks of emicizumab prophylaxis.

Keyphrases

public health
healthcare
bone mineral density
mental health
health information
gestational age
bone loss
health promotion
bone regeneration
postmenopausal women